TAOK3 and breast cancer: Because taxane-based adjuvant chemotherapy is used in most cases of high-risk breast cancer, we focused on patients with subsequent adjuvant chemotherapy (except endocrine therapy); we found that higher TAOK3 expression was significantly correlated to poor recurrence-free survival (HR = 1.7(1.2–2.41), p = 0.0024) (Fig. 8a) rather than post progression survival (Fig. 8b).